Humana Stock Price, News & Analysis

Humana Inc. (NYSE: HUM) will report its 1Q22 financial results on April 27, 2022, at 6:30 a.m. Eastern time. A conference call will follow at 9:00 a.m. to discuss the results and 2022 earnings guidance. Participants can register in advance for the call via a provided link, and a webcast will be available on Humana's Investor Relations page. The earnings release will include non-GAAP financial measures and a reconciliation to GAAP. Archived presentations will be accessible later on the website.

AM Best has assigned a Long-Term Issue Credit Rating of “bbb-” (Good) to Humana Inc. (HUM) for its recent issuance of $750 million in 3.70% senior unsecured notes due 2029. The outlook for this rating is stable, and Humana's overall financial health remains unchanged. Proceeds will support general corporate purposes and debt management, with Humana aiming for a more conservative long-term debt-to-capital ratio of 35%. Despite elevated financial leverage at 44%, operating cash flow is strong at $2.3 billion, contributing to favorable revenue growth.

Humana Inc. (NYSE: HUM) has successfully completed a public offering of $750 million in senior notes at a 3.700% interest rate, maturing in 2029. The net proceeds, estimated at $741.1 million, will be used for general corporate purposes, including repaying existing debt. Citigroup Global Markets and Morgan Stanley acted as joint book-running managers for the offering. Forward-looking statements caution investors about various risks, including healthcare cost management, government regulation, and potential impacts from the ongoing COVID-19 pandemic.

Humana Inc. (NYSE: HUM) has announced the pricing of a public offering for $750 million in 3.700% senior notes due 2029. The offering is set to close on March 23, 2022, pending standard closing conditions. The company anticipates net proceeds of approximately $741.1 million, which will be used for general corporate purposes, including repaying existing debts. Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are the joint book-running managers for this offering. This offering is part of an effective shelf registration with the SEC.

Humana has begun transitioning its Kindred at Home brand to CenterWell Home Health, strengthening its commitment to quality home care. This rebranding effort, initiated on March 1, 2022, will occur across seven states initially, with further expansions planned. The change aims to integrate Kindred's home health services into Humana's overall strategy, enhancing care continuity for patients. CenterWell will serve over 350 locations in 38 states, focusing on improving patient health outcomes and providing personalized care to Medicaid and Medicare patients.

Humana Inc. (NYSE: HUM) has elected David T. Feinberg, M.D., M.B.A., to its Board of Directors. With over 25 years of experience, Feinberg is currently the CEO of Cerner and previously led Google Health, enhancing healthcare initiatives using technology and innovation. Humana's Chairman, Kurt J. Hilzinger, emphasized Feinberg's expertise in improving clinical care and digital transformation as beneficial for the company's growth and strategy execution. This appointment increases Humana's board to 14 members.

Humana Inc. (NYSE: HUM) has announced that Chief Financial Officer Susan M. Diamond will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2022, at 9:30 a.m. Eastern time. Investors can access a live audio webcast of the presentation on Humana's Investor Relations page. The company emphasizes its commitment to integrated care, aiming to improve the health and well-being of its members while lowering costs. Humana supports healthcare professionals through various clinical capabilities and resources.

Humana Inc. (NYSE: HUM) announced a plan to enhance its Board of Directors by appointing two new independent directors as part of a cooperation agreement with Starboard Value LP. This initiative aims to improve corporate governance and align with the company's growth strategies. Humana reiterated its long-term earnings growth target of 11-15% and a $1 billion value creation goal by 2023, while also focusing on expanding its Medicare Advantage market share and increasing pre-tax margins.

Humana Inc. (NYSE: HUM) has declared a cash dividend of $0.7875 per share, reflecting a 12.5% increase from the previous $0.70 dividend. This dividend is payable on April 29, 2022, to stockholders of record as of March 31, 2022. Humana aims to enhance health outcomes and manage costs through integrated care, benefiting millions of members, including Medicare recipients and military personnel. The company provides a range of resources, such as in-home care and behavioral health services, to simplify healthcare access and improve member well-being.